Resultados globales: 5 registros encontrados en 0.02 segundos.
Artículos, Encontrados 5 registros
Artículos Encontrados 5 registros  
1.
9 p, 1.1 MB Epigenetic-Transcriptional Regulation of Fatty Acid Metabolism and Its Alterations in Leukaemia / Maher, Michael (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Diesch, Jeannine (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Casquero, Raquel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Buschbeck, Marcus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
In recent years fatty acid metabolism has gained greater attention in haematologic cancers such as acute myeloid leukaemia. The oxidation of fatty acids provides fuel in the form of ATP and NADH, while fatty acid synthesis provides building blocks for cellular structures. [...]
2018 - 10.3389/fgene.2018.00405
Frontiers in genetics, Vol. 9 (september 2018)  
2.
25 p, 1.1 MB Post-Translational Modifications of H2A Histone Variants and Their Role in Cancer / Corujo, David (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Buschbeck, Marcus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Histone variants are chromatin components that replace replication-coupled histones in a fraction of nucleosomes and confer particular characteristics to chromatin. H2A variants represent the most numerous and diverse group among histone protein families. [...]
2018 - 10.3390/cancers10030059
Cancers, Vol. 10 (february 2018)  
3.
16 p, 4.4 MB Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes / Palau, Anna (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Garz, Anne-Kathrin (German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany) ; Diesch, Jeannine (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zwick, Anabel (Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany) ; Malinverni, Roberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Valero, Vanesa (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Lappin, Katrina (Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom) ; Casquero, Raquel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Lennartsson, Andreas (Current address: Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden) ; Zuber, Johannes (Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria) ; Navarro, Tomàs (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mills, Ken I. (Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom) ; Götze, Katharina S. (German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany) ; Buschbeck, Marcus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Genetic lesions affecting epigenetic regulators are frequent in myelodysplastic syndromes (MDS). Polycomb proteins are key epigenetic regulators of differentiation and stemness that act as two multimeric complexes termed polycomb repressive complexes 1 and 2, PRC1 and PRC2, respectively. [...]
2017 - 10.18632/oncotarget.22839
Oncotarget, Vol. 8 (december 2017) , p. 115002-115017  
4.
17 p, 3.5 MB Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency / Muñoz López, Álvaro (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Romero Moya, Damià (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Prieto, Cristina (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Ramos Mejía, Verónica (Centro Pfizer - Universidad de Granada - Junta de Andalucía de Genómica e Investigación Oncológica) ; Agraz Doblas, Antonio (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Varela, Ignacio (Instituto de Biomedicina y Biotecnología de Cantabria) ; Buschbeck, Marcus (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Palau, Anna (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Carvajal Vergara, Xonia (Universidad de Navarra. Centro de Investigación Médica Aplicada) ; Giorgetti, Alessandra (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Ford, Anthony (Institute of Cancer Research (London, Gran Bretanya)) ; Lako, Majlinda (Newcastle University. Institute of Genetic Medicine) ; Granada i Font, Isabel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ruiz Xivillé, Neus (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rodríguez Perales, Sandra (Centro Nacional de Investigaciones Oncológicas) ; Torres Ruíz, Raúl (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Stam, Ronald W. (Erasmus University Medical Center (Rotterdam, Holanda)) ; Fuster, José Luis (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia)) ; Fraga, Mario F. (Instituto Universitario de Oncología del Principado de Asturias (Oviedo)) ; Nakanishi, Mahito (National Institute of Advanced Industrial Science and Technology (Tsukuba, Japó)) ; Cazzaniga, Gianni (Università degli Studi di Milano-Bicocca) ; Bardini, Michela (Università degli Studi di Milano-Bicocca) ; Cobo, Isabel (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Bayón, Gustavo F. (Instituto Universitario de Oncología del Principado de Asturias (Oviedo)) ; Fernández, Agustín F. (Instituto Universitario de Oncología del Principado de Asturias (Oviedo)) ; Bueno, Clara (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras) ; Menéndez, Pablo (Universitat de Barcelona (Campus Clínic). Institut de Recerca contra la Leucèmia Josep Carreras)
Induced pluripotent stem cells (iPSCs) are a powerful tool for disease modeling. They are routinely generated from healthy donors and patients from multiple cell types at different developmental stages. [...]
2016 - 10.1016/j.stemcr.2016.08.013
Stem cell reports, Vol. 7 Núm. 4 (October 2016)  
5.
11 p, 577.8 KB A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers / Diesch, Jeannine (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zwick, Anabel (Technical University Munich. Department of Medicine) ; Garz, Anne-Kathrin (German Cancer Research Center (Heidelberg, Alemanya)) ; Palau, Anna (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Buschbeck, Marcus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Götze, Katharina S. (German Cancer Research Center (Heidelberg, Alemanya))
The azanucleosides azacitidine and decitabine are currently used for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible for intensive chemotherapy but are also being explored in other hematologic and solid cancers. [...]
2016 - 10.1186/s13148-016-0237-y
Clinical epigenetics, Vol. 8 Núm. 71 (Juny 2016)  

Vea también: autores con nombres similares
2 Buschbeck, M.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.